Top-Rated StocksTop-RatedNASDAQ:PRTA Prothena (PRTA) Stock Forecast, Price & News $47.60 +0.30 (+0.63%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$45.22▼$47.9350-Day Range$47.30▼$69.0552-Week Range$28.99▼$79.65Volume576,001 shsAverage Volume394,026 shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/APrice Target$87.56 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Prothena MarketRank™ ForecastAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside83.9% Upside$87.56 Price TargetShort InterestBearish7.70% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.19Based on 9 Articles This WeekInsider TradingSelling Shares$4.14 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.99) to ($4.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.85 out of 5 starsMedical Sector721st out of 963 stocksPharmaceutical Preparations Industry329th out of 446 stocks 3.5 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $87.56, Prothena has a forecasted upside of 83.9% from its current price of $47.60.Amount of Analyst CoverageProthena has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.70% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Prothena has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 2.1 News and Social Media Coverage News SentimentProthena has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Prothena this week, compared to 3 articles on an average week.Search Interest7 people have searched for PRTA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows1 people have added Prothena to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,139,550.00 in company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($2.99) to ($4.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -17.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -17.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Prothena (NASDAQ:PRTA) StockProthena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.Read More PRTA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Upgraded to "Hold" at StockNews.comSeptember 23, 2023 | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) to Post Q1 2024 Earnings of ($1.34) Per Share, Zacks Research ForecastsSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 21, 2023 | seekingalpha.comProthena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug PromiseSeptember 20, 2023 | americanbankingnews.comProthena (NASDAQ:PRTA) Downgraded by StockNews.com to SellSeptember 20, 2023 | finance.yahoo.comInsider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLCSeptember 16, 2023 | finance.yahoo.comPinning Down Prothena Corporation plc's (NASDAQ:PRTA) P/S Is Difficult Right NowSeptember 14, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLCSeptember 27, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 7, 2023 | finance.yahoo.comProthena (PRTA) Skyrockets 88.7% in 12 Months: Here's WhyAugust 4, 2023 | markets.businessinsider.comRBC Capital Keeps Their Hold Rating on Prothena (PRTA)August 4, 2023 | markets.businessinsider.comJMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To KnowAugust 4, 2023 | finance.yahoo.comProthena (PRTA) Q2 Earnings and Revenues Miss EstimatesAugust 2, 2023 | benzinga.comProthena Corp's Earnings OutlookAugust 2, 2023 | finance.yahoo.comProthena Corporation plc (NASDAQ:PRTA) Shares Could Be 36% Below Their Intrinsic Value EstimateJuly 28, 2023 | finanznachrichten.deProthena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau AntibodyJuly 27, 2023 | seekingalpha.comProthena: Dunn Appointment And Bristol Opt-In Boost ValidationJuly 19, 2023 | fool.comProthena Plc (NASDAQ: PRTA)July 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Masimo (MASI)July 11, 2023 | msn.comExpert Ratings for Prothena CorpJuly 11, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Prothena (PRTA)July 11, 2023 | finance.yahoo.comProthena (PRTA) Alzheimer's Disease Drug Licensed by BMYJuly 11, 2023 | markets.businessinsider.comProthena (PRTA) Receives a Buy from Bank of America SecuritiesJuly 11, 2023 | markets.businessinsider.comProthena (PRTA) Receives a Buy from JMP SecuritiesJuly 10, 2023 | businesswire.comProthena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau AntibodyJuly 10, 2023 | bizjournals.comPeninsula biotech lands $55M as Big Pharma exercises option on Alzheimer's drugJune 21, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Exact Sciences (EXAS) and Prothena (PRTA)See More Headlines Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Company Calendar Last Earnings8/03/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees127Year FoundedN/APrice Target and Rating Average Stock Price Forecast$87.56 High Stock Price Forecast$129.00 Low Stock Price Forecast$55.00 Forecasted Upside/Downside+83.9%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,950,000.00 Net Margins-244.45% Pretax Margin-266.80% Return on Equity-25.43% Return on Assets-20.31% Debt Debt-to-Equity RatioN/A Current Ratio9.46 Quick Ratio9.46 Sales & Book Value Annual Sales$53.90 million Price / Sales47.27 Cash FlowN/A Price / Cash FlowN/A Book Value$12.86 per share Price / Book3.70Miscellaneous Outstanding Shares53,530,000Free Float38,438,000Market Cap$2.55 billion OptionableOptionable Beta0.39 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Gene G. Kinney Ph.D. (Age 54)Pres, CEO & Director Comp: $1.03MMr. Tran B. Nguyen M.B.A. (Age 49)CFO & Chief Strategy Officer Comp: $762.86kMr. Brandon S. Smith (Age 48)Chief Operating Officer Comp: $756.41kMs. Carol D. Karp (Age 70)Chief Regulatory Officer Comp: $697.51kDr. Hideki Garren M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $809.59kMs. Karin L. Walker CPA (Age 60)CPA, Chief Accounting Officer & Controller Dr. Wagner M. Zago (Age 50)Chief Scientific Officer Ms. Jennifer ZibudaDirector of Investor Relations & CommunicationMr. Michael J. Malecek (Age 57)Chief Legal Officer & Company Sec. More ExecutivesKey CompetitorsAkero TherapeuticsNASDAQ:AKROUltragenyx PharmaceuticalNASDAQ:RARENuvalentNASDAQ:NUVLMirati TherapeuticsNASDAQ:MRTXMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsBarclays PLCBought 3,208 shares on 9/21/2023Ownership: 0.127%Karin L. WalkerSold 5,000 sharesTotal: $261,800.00 ($52.36/share)Brandon S. SmithSold 4,000 sharesTotal: $221,960.00 ($55.49/share)Hideki GarrenSold 2,000 sharesTotal: $110,960.00 ($55.48/share)Carol D. KarpSold 5,000 sharesTotal: $273,800.00 ($54.76/share)View All Insider TransactionsView All Institutional Transactions PRTA Stock - Frequently Asked Questions Should I buy or sell Prothena stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares. View PRTA analyst ratings or view top-rated stocks. What is Prothena's stock price forecast for 2023? 10 analysts have issued 12 month target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $129.00. On average, they predict the company's stock price to reach $87.56 in the next year. This suggests a possible upside of 83.9% from the stock's current price. View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts. How have PRTA shares performed in 2023? Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA shares have decreased by 21.0% and is now trading at $47.60. View the best growth stocks for 2023 here. When is Prothena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our PRTA earnings forecast. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) issued its earnings results on Thursday, August, 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.11. The biotechnology company earned $4.02 million during the quarter, compared to the consensus estimate of $5.09 million. Prothena had a negative trailing twelve-month return on equity of 25.43% and a negative net margin of 244.45%. The company's quarterly revenue was up 206.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) earnings per share. What ETFs hold Prothena's stock? ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD). What is Prothena's stock symbol? Prothena trades on the NASDAQ under the ticker symbol "PRTA." Who are Prothena's major shareholders? Prothena's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.75%), State Street Corp (3.50%), Dimensional Fund Advisors LP (2.15%), Geode Capital Management LLC (1.57%), Bank of New York Mellon Corp (0.97%) and Nuveen Asset Management LLC (0.85%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Prothena's stock price today? One share of PRTA stock can currently be purchased for approximately $47.60. How much money does Prothena make? Prothena (NASDAQ:PRTA) has a market capitalization of $2.55 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. How many employees does Prothena have? The company employs 127 workers across the globe. How can I contact Prothena? Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510. This page (NASDAQ:PRTA) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.